Study of rifampicin resistance among newly diagnosed pulmonary tuberculosis patients with type 2 diabetes mellitus: a prospective observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20212526Keywords:
TB, DM, Rifampicin resistance, CBNAATAbstract
Background: Rifampicin (RIF) resistance in new cases of pulmonary tuberculosis is a matter of concern. Diabetes Mellitus triples the risk of developing tuberculosis. Early detection of TB and its resistance status in diabetics can help in improving the care and treatment outcomes of both diseases.
Methods: It was a prospective study conducted from February 2019 to March 2020 in PGIMS, Rohtak on 50 patients of DM with newly diagnosed Pulmonary TB. Rifampicin resistance was detected by CBNAAT on sputum, induced sputum and BAL samples.
Results: Mean age of study subjects was 51.24±10.421 (in years) with M: F ratio of 3:1 and maximum patients in 50-59 age group. The average BMI in patients was 22.49±2.42 kg/m2. The most common presenting complaint was cough (92%) followed by fever (68%). Mean serum HBA1c was 9.66±2.24 and mean FBS and PPBS was 195.81±59.08 and 302.02±99.01 mg/dl respectively. Out of 36 cases who gave sputum, 29 (80.55%) were detected rifampicin sensitive and 7 (19.44%) were rifampicin resistant whereas out of 11 who were induced, 9 (81.8%) were rifampicin sensitive and 2(18.18%) were rifampicin resistant. Out of 3 cases detected by BAL CBNAAT, 2 (66.6%) were rifampicin sensitive and 1 (33.33%) was rifampicin resistant. Overall, 10(20%) patients were detected Rifampicin resistant by CBNAAT.
Conclusions: We found that TB-DM patients had a higher proportion of drug resistance (20%), so DM should be considered as an independent risk factor for MDR-TB and effective measures are required for early diagnosis of MDR-TB.
References
Global tuberculosis report 2019. World Health Organization, Geneva. 2019. Available at: https://www.who.int/tb/publications/global_report/en/. Last accessed 10 May 2021.
Maher D. The natural history of Mycobacterium tuberculosis infection in adults. In: Schaaf HS, Zumla A, editors. Tuberculosis: A Comprehensive Clinical Reference. 1st Edition Elsevier Health Sci. 2009;129-32.
Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis. 2007;45(4):436‐8.
Global tuberculosis report 2017. World Health Organization, Geneva. 2017. Available at: https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf?ua=1. Last accessed 10 May 2021.
Singh R, Gothi D, Joshi J M. Multidrug resistant tuberculosis: Role of previous treatment with second line therapy on treatment outcome. Lung India. 2007;24:54-7.
Aragon J., Litonjua A., Tupasi T., Quela I. Prevalence of type 2 diabetes among multi-drug resistant tuberculosis (MDR-TB) patients seen in Makati Medical Center under the directly observed therapy plus (DOTS PLUS) program. Philippine Journal of Internal Medicine. 2003;41:7-10.
Williams R, Colagiuri S, Chan J, Gregg EW, Ke C, Lim LL, et al. IDF Atlas 9th Edition 2019. International Diabetes Federation 2019. Available at https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Last accessed 10 May 2021.
Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and pre-diabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54(12):3022-7.
Vellalacheruvu BN, Bekur R, Mapakshi H. Effect of type 2 diabetes mellitus on presentation and treatment response of sputum positive pulmonary tuberculosis. Int J Sci R Pub. 2015;5(9).
Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis. 2008;40(11-12):888-93.
Tuberculosis and Diabetes. World Health Organization, Geneva. 2016. Available at: http://www.who.int/tb/publications/global_report/e. Last accessed 10 May 2021.
Nissapatorn V, Kuppusamy I, Jamaiah I, Fong MY, Rohela M, Anuar AK. Tuberculosis in diabetic patients: a clinical perspective. Southeast Asian J Trop Med Public Health. 2005;36(4):213-20.
Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care. 2004;27(7):1584-90.
Manjareeka M, Palo SK, Swain S, Pati S, Pati S. Diabetes Mellitus among Newly Diagnosed Tuberculosis Patients in Tribal Odisha: An Exploratory Study. J Clin Diagn Res. 2016;10(10):LC06-8.
Rawat J, Sindhwani G, Biswas D. Effect of age on presentation with diabetes: Comparison of non diabetic patients with new smear-positive pulmonary tuberculosis patients. Lung India. 2011;28:187-90.
Khalil N, Ramadan RA. Study of risk factors for pulmonary tuberculosis among diabetes mellitus patients. Egypt J Chest Dis Tuberc. 2016;65:817-23.
Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis. 1982;125(3P2):8-15.
Magee MJ, Bloss E, Shin SS, Contreras C, Huaman H, Ticona J, et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis. 2013;17:404-12.
Kikvidze M, Mikiashvili L. Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia - Cohort study. Eur Respir J. 2013;42(57):2826.
Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Osman MM. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis. 2006;10(1):74-9.
Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45(4):428-35.
Baghaei P, Tabarsi P, Moniri A, Marjani M, Velayati A. Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. Int J Mycobact. 2015;4:128.
Chang JT, Dou HY, Yen CL, Wu YH, Huang RM, Lin HJ, et al. Effect of Type 2 Diabetes Mellitus on the Clinical Severity and Treatment Outcome in Patients with Pulmonary Tuberculosis: A Potential Role in the Emergence of Multidrug-resistance. J Formos Med Assoc. 2011;110:372-81.
Sinha S, Gupta K, Kohli M, Myneedu VP, Pandey RM, Singh PP. Prevalence of Multi-Drug Resistant Tuberculosis among New Culture- Positive Pulmonary Tuberculosis Patients in Tertiary Care Center of North India. J Tuberc Ther. 2018; 3(2):116.
Gautam PB, Mishra A, Kumar S. Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study. Int J Community Med Public Health. 2018;5(6):2271-6.
Charan J, Tank N, Reljic T, Singh S, Bhardwaj P, Kaur R, et al. Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis. J Family Med Prim Care. 2019;8:3191-201.
Lohiya A, Suliankatchi Abdulkader R, Rath RS, Jacob O, Chinnakali P, Goel AD, et al. Prevalence and patterns of drug resistant pulmonary tuberculosis in India-A systematic review and meta-analysis. J Glob Antimicrob Resist. 2020;22:308-16.
Arega B, Menbere F, Getachew Y. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infect Dis. 2019;19:307.
Saurabh M, Yu EA, Fazil AS, Wesley B, John K. Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India. BMC Infectious Diseases. 2015;15:451.
Mi F, Jiang G, Du J, Li L, Yue W, Harries AD et al. Is resistance to anti-tuberculosis drugs associated with type 2 diabetes mellitus? A register review in Beijing, China. Global Health Action. 2014;(7)1:24022.
Wanmei S, Yang S, Jinyue L, Ningning T, Yao L, Qianyun Z et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: a retrospective study among 7223 cases in China. Infection and Drug Resistance. 2019;12:2397-407.
Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis. 2017;103:83-91.
Liu Q, Li W, Xue M. Diabetes mellitus and the risk of multidrug resistant tuberculosis : a meta-analysis. Sci Rep. 2017;7(1):1090.
